dc.contributor.author |
Starostina I. |
|
dc.contributor.author |
Solovyeva V. |
|
dc.contributor.author |
Yuryeva K. |
|
dc.contributor.author |
Shevchenko K. |
|
dc.contributor.author |
Fedotov V. |
|
dc.contributor.author |
Rizvanov A. |
|
dc.contributor.author |
Deev R. |
|
dc.contributor.author |
Isaev A. |
|
dc.date.accessioned |
2018-09-18T20:30:48Z |
|
dc.date.available |
2018-09-18T20:30:48Z |
|
dc.date.issued |
2013 |
|
dc.identifier.issn |
1815-445X |
|
dc.identifier.uri |
https://dspace.kpfu.ru/xmlui/handle/net/140648 |
|
dc.description.abstract |
Dysferlinopathies is a group of autosomal-recessive inherited neuromuscular diseases, which are characterized by defect in mRNA expression or in functionioning of dysferlin protein, appearing in about 1/200 000 births. Dysferlin is encoded by DYSF gene (Dystrophy-associated fer-1- like). It's disruption can cause various types of primary dysferlinopathies, which include Miyoshi myopathy (MM), Limb-girdle Muscular Dystrophy type 2B (LGMD2B) and distal myopathy with anterior tibial onset. Also, dysferlin deficiency can be associated with other diseases, such as caveolin- And calpainopathies. Here we discuss dysferlin protein structure and function, it's clinical phenotypes, known animal models and developing treatment strategies for dysferlinopathies. © Human stem cells institute, 2013. |
|
dc.relation.ispartofseries |
Cellular Transplantation and Tissue Engineering |
|
dc.subject |
Distal myopathy with anterior tibial onset |
|
dc.subject |
Dysferlin |
|
dc.subject |
Dysferlinopathy |
|
dc.subject |
Limb girdle muscular dystrophy |
|
dc.subject |
Miyoshi myopathy |
|
dc.title |
Modeling and gene therapy of dysferlinopathy |
|
dc.type |
Review |
|
dc.relation.ispartofseries-issue |
3 |
|
dc.relation.ispartofseries-volume |
8 |
|
dc.collection |
Публикации сотрудников КФУ |
|
dc.relation.startpage |
61 |
|
dc.source.id |
SCOPUS1815445X-2013-8-3-SID84887112580 |
|